By ED SILVERMAN
For instance, in an investor note, Sanford Bernstein analyst Geoff Porges wrote that Gilead left AbbVie “less room to start a price war” than some may have expected. How so? Gilead priced the eight-week regimen at $63,000, which means average pricing for Harvoni would be about $80,000, assuming that as many as 45% of the patients with most common form of the virus use the drug for eight weeks.
This is actually less than what most insurers are now paying for Sovaldi, which costs $84,000 for a 12-week regimen, but must be taken with another drug. This pushes the cost to somewhere between $95,000 or so and $160,000, depending upon which medication is added. In short, the Gilead maneuver may place added pressure on AbbVie to consider aggressive pricing.Continue Reading @ WSJ....
Related On The Blog
Reducing the cost of new hepatitis C drugs
An index of articles pointing the reader to current controversy over the price of Harvoni (ledipasvir/sofosbuvir) and Sovaldi.
The situation has Medicaid plans and insurers nationwide groping for the right balance. Worldwide patients are unable to afford treatment, while others wait in the wings on coverage.
The situation has Medicaid plans and insurers nationwide groping for the right balance. Worldwide patients are unable to afford treatment, while others wait in the wings on coverage.
